22.02.2013 - Molecular diagnostics and lab provider Qiagen is entering the highly competitive market of Next-Generation Sequencing (NGS) benchtop sequencers.
The company presented a sample-to-result Next-Generation Sequencing workflow designed for clinical research and diagnostics at the AGBT meeting in Florida. However, its sample preparation, newly introduced benchtop sequencer GeneReaderTM and bioinformatics solution is for research use only, as those are of its competitors Roche, Illumina and Life Technologies. However, the announcement suggested that the Dutch-German company’s NGS workflow is automated from primary sample to digital result.
"Next-generation sequencing is making a transformational impact on life science, but challenges are limiting more widespread adoption for clinical purposes," said Peer M. Schatz, CEO of QIAGEN. "The development of our complete sample-to-result workflow is a key achievement in our initiative to offer a seamless integration of new NGS platforms with high-quality reagents, molecular testing content and services."
No sequencing firm currently has a NGS workflow that is simple and reliable enough for diagnostic purposes. However, all of them aim at establishing highly automated and inter-laboratory reproducible NGS procedures that can be used by non-specialists. The adoption of NGS in fields such as clinical research and diagnostics is still hampered by workflow challenges, manual sample preparation processes, the speed, comparability and quality of data analysis.
16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.
10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.
05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.
03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.